IPO and L/S equity, 2015 Starmine top stock picker, Global Equity Research Ltd

Rickin Thakrar

14 years of experience in global investment research and trading. In relation to research, we focus on IPO, Event-driven and large-cap non-consensual ideas. In relation to trading, we focus on generating positive index-adjusted returns and have had several top-decile or top-quartile performances over the past three years. In terms of background, I have worked at several sell-side firms (JP, Redburn, Haitong, Mainfirst), won Starmine as top stock picker in European Food Retail in 2015 and have been voted top one to top-five by institutions and hedge funds.

IPO and L/S equity, 2015 Starmine top stock picker

Takara Leben REIT Placement: Fully Priced Acquisitions

FINEOS IPO Initiation: Claiming the Cloud

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week, we dig into the stretched balance sheet and cash generation concerns for the IPO of <a href="https://www.smartkarma.com/entities/the-we-company-wework" target="_blank" data-smartkarma-citation="entities:28061:1" rel="noopener">The We Company (WeWork) (WE US)</a> while we like the fundamentals for the IPO of biotech company <a href="https://www.smartkarma.com/entities/venus-medtech-hangzhou-inc" target="_blank" data-smartkarma-citation="entities:28257:1" rel="noopener">Venus MedTech Hangzhou Inc (1392140D CH)</a>. Finally, on the IPO side, we continue to believe SaaS operator <a href="https://www.smartkarma.com/entities/fineos-corp-holdings-plc-cdi" target="_blank" data-smartkarma-citation="entities:28218:1" rel="noopener">FINEOS (FCL AU)</a> is overvalued. In placement research, we recommend taking the deal on <a href="https://www.smartkarma.com/entities/takara-leben-co-ltd" target="_blank" data-smartkarma-citation="entities:15969:1" rel="noopener">Takara Leben (8897 JP)</a> . On the M&amp;A side, we believe the bid for <a href="https://www.smartkarma.com/entities/tpv-technology-ltd" target="_blank" data-smartkarma-citation="entities:17232:1" rel="noopener">TPV Technology (903 HK)</a> merits a bump. To conclude, we recap on the fundamental contrasts between <a href="https://www.smartkarma.com/entities/douyu-international-hold-adr" target="_blank" data-smartkarma-citation="entities:28045:1" rel="noopener">Douyu International Holdings (DOYU US)</a> as a more robust operator vs. <a href="https://www.smartkarma.com/entities/huya-inc" target="_blank" data-smartkarma-citation="entities:26983:1" rel="noopener">HUYA Inc (HUYA US)</a>.More details can be found below. Best of luck for the rest of the week - Rickin, Arun and Venkat

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week, we dig into the stretched balance sheet and cash generation concerns for the IPO of The We Company (WeWork) (WE US) while we like the fundamentals for the IPO of biotech company Venus MedTech Hangzhou Inc (1392140D CH). Finally, on the IPO side, we continue to believe SaaS operator FINEOS (FCL AU) is overvalued. In placement research, we recommend taking the deal on Takara Leben (8897 JP) . On the M&amp;A side, we believe the bid for TPV Technology (903 HK) merits a bump. To conclude, we recap on the fundamental contrasts between Douyu International Holdings (DOYU US) as a more robust operator vs. HUYA Inc (HUYA US).More details can be found below. Best of luck for the rest of the week - Rickin, Arun and Venkat

Takara Leben Real Estate Investment Corp (3492 JP)

Last Week in GER Research: WeWork, Venus Medtech, Fineos, Takara Leben, TPV Tech, and Douya/Huya